Almonertinib mesylate
Modify Date: 2024-01-09 16:19:19
Almonertinib mesylate structure
|
Common Name | Almonertinib mesylate | ||
|---|---|---|---|---|
| CAS Number | 2134096-06-1 | Molecular Weight | 621.75 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C31H39N7O5S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of Almonertinib mesylateAlmonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer[1][2]. |
| Name | Almonertinib mesylate |
|---|
| Description | Almonertinib (HS-10296) mesylate is an orally available, irreversible, third-generation EGFR tyrosine kinase inhibitor with high selectivity for EGFR-sensitizing and T790M resistance mutations. Almonertinib mesylate shows great inhibitory activity against T790M, T790M/L858R and T790M/Del19 (IC50: 0.37, 0.29 and 0.21 nM, respectively), and is less effective against wild type (3.39 nM). Almonertinib mesylate is used for the research of the non-small cell lung cancer[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | HS-10296 mesylate is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity, which canbe used to treat NSCLC[2]. Additionaly, HS-10296 mesylate could also inhibit other EGFR sensitive mutations, including G719X, del19, L858R and L861Q[3]. |
| References |
| Molecular Formula | C31H39N7O5S |
|---|---|
| Molecular Weight | 621.75 |